June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Specific Inhibition of inflammatory corneal lymphangiogenesis by topical application of Sema3F
Author Affiliations & Notes
  • Felix Bock
    Ophthalmology, University of Cologne, Cologne, Germany
  • Ann-Charlott Schneider
    Ophthalmology, University of Cologne, Cologne, Germany
  • Andreas Stahl
    Department of Ophthalmology, University of Freiburg, Freiburg, Germany
  • Tristan Reuer
    Department of Ophthalmology, University of Freiburg, Freiburg, Germany
  • Claus Cursiefen
    Ophthalmology, University of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships   Felix Bock, None; Ann-Charlott Schneider, None; Andreas Stahl, None; Tristan Reuer, None; Claus Cursiefen, None
  • Footnotes
    Support  FOR 2240
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1006. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Felix Bock, Ann-Charlott Schneider, Andreas Stahl, Tristan Reuer, Claus Cursiefen; Specific Inhibition of inflammatory corneal lymphangiogenesis by topical application of Sema3F
      . Invest. Ophthalmol. Vis. Sci. 2017;58(8):1006.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
Inflammatory corneal hem- and lymphangiogenesis is the major risk factor for immune rejections after penetrating keratoplasty. Semaphorin 3F (Sema3F) has been shown to suppress lymphangiogenesis in several settings. Purpose of this study was to investigate whether the same effect could be achieved by local application of Sema3F.

Methods :
Three interrupted 11-0 nylon sutures were placed into the corneal stroma of BALB/c mice (6 weeks old) and left in place for 14 days to induce neovascularization. The treatment group (n=10) received Sema3F as eye drops three times per day (50µg/drop). Control mice received an equal amount of PBS. For immunohistochemistry, corneal flat mounts were stained with LYVE-1 as a specific lymphatic vascular endothelial marker and CD31 as pan endothelial marker. Morphometry was performed with the image analysis software Cell^F (Olympus, Germany). Additionally, macrophages in the cornea as well as from the draining lymph nodes were analysed.

Results :
Sema3F treated mice showed a significant and specific downregulation of lymphangiogenesis compared with PBS control mice (p<0.001), whereas hemangiogenesis and macrophage frequency was not affected.

Conclusions :
Corneal lymphangiogenesis is significantly impaired by applying Sema3F topically as eye drops. This effect could be exploited to inhibit lymphangiogenesis after corneal transplantation to promote graft survival.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×